Brief: Astrazeneca Pharma India Received No Objection From Central Drugs Standard Control Organisation
14/02/2023 13:22
Feb 14 (Reuters) - Astrazeneca Pharma India Ltd
ASTR.NS :
* RECEIVED NO OBJECTION FOR AN ADDITIONAL/EXPANDED
INDICATION FROM
THE CENTRAL DRUGS STANDARD CONTROL ORGANISATION
* RECEIVED NO OBJECTION FOR DURVALUMAB (IMFINZI™) 120 MG/
2.4 ML
AND 500 MG/ 10 ML SOLUTION FOR INFUSION
Source text for Eikon: ID:
Further company coverage: ASTR.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan